| Medicine |
|
|
|
|
| Quality of life and cost-effectiveness of combined therapy for reflux esophagitis |
| SI Jian-min, WANG Liang-jing, CHEN Shu-jie, ZHAO Lan, DAI Ning |
| Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China |
|
|
|
Abstract Objective: To evaluate clinical, Quality of Life (QoL) and medical cost outcomes in patients with symptomatic reflux esophagitis (RE) receiving different \"triple combination therapy\". Methods: A multicenter medical effectiveness trial conducted in 10 hospitals of 5 regions in Zhejiang Province. 248 patient-volunteers were assigned to 8 weeks of \"triple combination therapy\" with Lansoprazole plus Cisapride and Sucralfate or Ranitidine plus Cisapride and Sucralfate. Main outcomes assessment included symptoms scale scores, RE severity, QoL at baseline and 8 weeks. Medical cost data were collected with cost analysis questionnaire. Results: (1) More Lansoprazole group patients noted RE symptoms resolution than Ranitidine group (92.3% vs 78.4%, P<0.01). There was no striking difference between two groups in RE healing rate (90.8% vs 82.9%, P>0.05). (2) RE significantly impaired QoL of patients (P<0.001).Compared with Ranitidine group, QoL in Lansoprazole group had significant improvement (rate of \"good\" QoL 64.5% vs 45.6%, P<0.01). (3)There was close correlation between symptomic effectiveness and QoL rating scale in both the Lansoprazole and Ranitidine group (P<0.01, r=0.235 and 0.353 respectively). There were no statistical difference of medical cost between the two groups (P>0.05). Conclusion: RE significantly impaired QoL of patients. \"Triple combination therapies\" can significantly improve RE symptoms and QoL. Lansoprazole combination therapy was more cost-effective than Ranitidine combination group.
|
|
Received: 29 August 2002
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
